Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Thera continues to post on cancer on Linkedin

<< Previous

Bullboard Posts

Next >>

Comment by TH1902on Sep 24, 2022 2:42pm

145 Views

Post# 34984328

RE:RE:RE:Thera continues to post on cancer on Linkedin

So JFM are you implying that you believe TH1902 1b will be successful based on this?

I also find it curious and reading through SPCEO's last long note, many reasons to think that something positive is about to happen.

Hope you are doing ok.

jfm1330 wrote: When they were actively pushing NASH, it was not during an ongoing open label clinical trial.

SABBOBCAT wrote: Remember when the company used to post about NASH and go to conference to talk it up? Good times LOL. In al seriousness I do think this time is finally different, but I think Mr Market has it right with the "I'll believe it when I see it" approach.